Cordance Medical is a neurotechnology company developing a focused ultrasound system designed to enable precision medicine for brain diseases by non-invasively opening the blood–brain barrier. The platform allows physicians to transiently and precisely open the BBB at targeted brain regions, such as tumor sites or areas of pathology, in a short outpatient procedure.

The technology is intended to enhance therapeutic delivery to the brain, accelerate drug development by improving target engagement, and enable liquid biopsy approaches that provide real-time insight into tumor biology. Extensive preclinical and clinical investigations have demonstrated the safety and feasibility of focused ultrasound–mediated BBB opening using this approach.

Cordance’s platform is applicable across a broad range of neurological and neurodegenerative conditions, including glioblastoma, brain metastases, Alzheimer’s disease, Parkinson’s disease, epilepsy, and mental health disorders. The company positions its system as an enabling infrastructure for next-generation CNS therapeutics rather than a standalone neuromodulation treatment.